

Entecavir (monohydrate)

Catalog No: tcsc1783



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg



Specifications

CAS No:

209216-23-9

Formula:

$C_{12}H_{17}N_5O_4$

Pathway:

Anti-infection

Target:

HBV

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 32 mg/mL (108.37 mM); H₂O : 2.8 mg/mL (9.48 mM); Need ultrasonic and warming)

Alternative Names:

SQ 34676;BMS-200475

Observed Molecular Weight:

295.29


Product Description

Entecavir monohydrate (SQ 34676; BMS 200475) is a potent and selective inhibitor of **HBV**, with an **EC₅₀** of 3.75 nM in HepG2 cell.

IC50 & Target: EC50□3.75 nM (anti-HBV, HepG2 cell)^[1]

In Vitro: BMS-200475 has a EC₅₀ of 3.75 nM against HBV. It is incorporated into the protein primer of HBV and subsequently inhibits the priming step of the reverse transcriptase. The antiviral activity of BMS-200475 is significantly less against the other RNA and DNA viruses^[1]. Entecavir is more readily phosphorylated to its active metabolites than other deoxyguanosine analogs (penciclovir, ganciclovir, lobucavir, and aciclovir) or lamivudine. The intracellular half-life of entecavir is 15 h^[2].

In Vivo: Daily oral treatment with BMS-200475 at doses ranging from 0.02 to 0.5 mg/kg of body weight for 1 to 3 months effectively reduces the level of woodchuck hepatitis virus (WHV) viremia in chronically infected woodchucks^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!